Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 10/20 | 1.00 |
| ▸ | JAK3 | P52333 | 6/20 | 0.72 |
| ▸ | JAK2 | O60674 | 4/20 | 0.72 |
| ▸ | JAK1 | P23458 | 3/20 | 0.72 |
| ▸ | TTK | P33981 | 1/20 | 0.72 |
| ▸ | TYK2 | P29597 | 1/20 | 0.71 |
| ▸ | EGFR | P00533 | 6/20 | 0.65 |
| ▸ | BLK | P51451 | 2/20 | 0.62 |
| ▸ | FLT3 | P36888 | 1/20 | 0.62 |
| ▸ | BMX | P51813 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15640174 | 0.94 | BTK (0.89) | BTKJAK3JAK2JAK1TTK | |
| SCHEMBL17071433 | 0.91 | BTK (0.85) | BTKJAK3JAK2JAK1TTK | |
| SCHEMBL10127962 | 0.91 | BTK (1.00) | BTKJAK3JAK2EGFRBLK | |
| SCHEMBL15638700 | 0.89 | BTK (1.00) | BTKJAK3JAK2JAK1TTK | |
| SCHEMBL17071407 | 0.89 | BTK (0.88) | BTKJAK3JAK2JAK1TTK | |
| SCHEMBL16144739 | 0.89 | BTK (0.80) | BTKJAK3JAK2JAK1TTK | |
| SCHEMBL14740394 | 0.89 | BTK (0.80) | BTKJAK3JAK2JAK1TTK | |
| SCHEMBL17071396 | 0.89 | BTK (0.88) | BTKJAK3JAK2JAK1TTK | |
| SCHEMBL15637442 | 0.89 | BTK (0.79) | BTKJAK3JAK2JAK1TTK | |
| SCHEMBL12813112 | 0.89 | BTK (1.00) | BTKJAK3JAK2JAK1TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694486-B1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIV UTAH RES FOUND (US) | 2018-01-10 | — | — | EP | disclosed |
| US-20160046586-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIV UTAH RES FOUND (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046586-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIV UTAH RES FOUND (US) | 2016-02-18 | — | — | US | disclosed |
| US-9206176-B2 | Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206176-B2 | Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-12-08 | — | — | US | disclosed |
| US-8703767-B2 | Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2694486-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | University of Utah Research Foundation (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20130059847-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH | 2013-03-07 | — | — | US | disclosed |
| US-20130059847-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH | 2013-03-07 | — | — | US | disclosed |
| WO-2012135801-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012135801-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046586-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | BTK, SYK, LYN | BTK 1/4885JAK3 58/4885JAK2 20/4885 |
| US-20130059847-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | BTK, SYK, LYN | BTK 1/4885JAK3 58/4885JAK2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.